Live news, investigations, opinion, photos and video by the journalists of The New York Times from more than 150 countries around the world. Subscribe for coverage of U.S. and international news, politics, business, technology, science, health, arts, spo
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860. doi:10.1182/blood-2013-01-466706PubMedGoogle ScholarCrossref 20. U.S. Food and Drug Administration. FDA news release: FDA ...
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3: 236–260. Article Google Scholar Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK ...
Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA Derek Klarin Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Derek Klarin & James B. Meigs Division of Vascular Surgery and Endovascular Therapy, University of Florida ...
OSAKA, Japan and CAMBRIDGE, Massachusetts, November 8, 2023– Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorect...
Eleven patients remained asymptomatic with appropriate nutritional therapy after a mean follow-up of 30 months, and one was symptomatic.40 These results highlight the effectiveness of NBS in detecting disease and positively impacting outcomes while emphasizing the role of additional biochemical, enzymatic...
D. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. Biochim. Biophys. Acta 1849, 821–829 (2015). Article CAS PubMed Google Scholar Golomb, L. Volarevic, S. & Oren, M. p53 and ribosome biogenesis stress: the essentials. FEBS Lett. ...
Michel Sadelain and Eirini P. Papapetrou are at the Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA., Michel Sadelain & Eirini P. Papapetrou
with approximately 80% of them being naïve B cells, while plasma cells remained at low levels. This result suggests that the long-term efficacy of CAR-T cell therapy may be related to the reconstitution of B cells with a predominantly naïve phenotype and the continued clearance of plasma...
et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518, 107–110 (2015). CAS PubMed Google Scholar Reshetnyak, Y. K., Andreev, O. A., Lehnert, U. & Engelman, D. M. Translocation of molecules into cells by pH-dependent insertion of a ...